 | This article needs to beupdated. Please help update this article to reflect recent events or newly available information.(January 2023) |
| Date | 27 December 2020 (2020-12-27) – present |
|---|---|
| Location | Hungary |
| Cause | COVID-19 pandemic in Hungary |
| Part ofa series on the |
| COVID-19 pandemic |
|---|
 |
|
Medical response |
|
.svg) COVID-19 portal |
COVID-19 vaccination in Hungary is an ongoingimmunization campaign againstsevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causescoronavirus disease 2019 (COVID-19), in response to theongoing pandemic in the country.
Around 20.13% of the Hungarian citizens (based on the 2011 census[1][2] and the official vaccination statistics) have received, at least, one anti-COVID-19 injection, since 28 March 2021.
 | This graph was using thelegacy Graph extension, which is no longer supported. It needs to be converted to thenew Chart extension. |
Reports in March 2021 stated that Hungary was the first country in the EU to "begin using China'sSinopharm BIBP and Russia'sSputnik V vaccines, even as polling showed that public trust in non-EU approved vaccines was low".[3] The European Commission's Vaccine Passport plan excluded the Sputnik and Sinopharm products because they were not "EU authorized vaccines". One suggestion to resolve that issue was that "Russian and Chinese vaccine producers submit their products to the EMA for testing and authorization".[4] At the end of March 2021, Hungary also granted emergency use licenses to two more vaccines, CanSino (from China) andCovishield (theAstraZeneca vaccine produced by theSerum Institute of India).[5]
| Vaccine | Approval | Deployment |
|---|---|---|
| Oxford–AstraZeneca |  Yes | Yes |
| Sinopharm BIBP | Yes | Yes |
| Pfizer–BioNTech | Yes | Yes |
| Moderna | Yes | Yes |
| Janssen | Yes | Yes |
| Sputnik V | Yes | Yes |
| Convidecia | Yes |  No |
| Novavax | Yes | No |
| Sanofi–GSK | Pending | No |
| CureVac | Pending | No |
| Valneva | Pending | No |
On 17 March 2020, the Surgeon General announced that the National Safety Laboratory of National Health Security Center had successfully isolated COVID-19 from a Hungarian patient's sample, which it could use for the research and development of a new Hungarian vaccine.[6][7] A consortium founded by the Department of Immunology at the Faculty of Sciences ofEötvös Loránd University, the Institute of Biology at the Science Faculty of theUniversity of Pécs,Richter Gedeon and ImmunoGenes is involved in international biotechnological developments.[8][9] Imre Kacskovics, leader of Immunology Department of ELTE, said the product currently in the first phase of development won't be a vaccine, but provide passiveimmunity. It will not prepare the body to fight against the virus.[10] Some days after the successful isolation, the Bioinformatic Research Team of Szentágothay János Research Center at the University of Pécs and the university's virologists made thegenome of the newSARS-CoV-2 human coronavirus available in Hungary.[11][12]